elea and Lumea have announced a strategic partnership, creating a Unified Pathology Ecosystem that collapses the wall between LIS and IMS into a  single, AI-native diagnostic workspace.

The partnership combines Lumea’s premier FDA-cleared diagnostic viewer with elea’s intuitive AI-native LIS, delivering what the two companies describe as an “always-on” agentic environment where data management and image analysis exist as one, built around the principle of One Screen,  One Workspace, Zero Friction.

At the core of the collaboration is Lumea’s Viewer+, which offers both a traditional digital pathology experience and a state-of-the-art diagnostic  operating system.
Paired with elea’s voice-driven AI, the integrated platform extracts structured data and prepares reports in real-time, eliminating  the friction of toggling between siloed software tools.
The unified ecosystem is designed for pathologists, lab leaders, and health systems alike.
For  pathologists, it enables hands-free navigation of complex cases through voice control and reduces administrative burden via AI-assisted reporting.
For lab leaders, the pre-integrated environment reduces time from sample to diagnosis and increases daily throughput without adding headcount.
For health systems, it offers a scalable, AI-ready infrastructure that bridges the gap between tissue and treatment while reducing turnaround time.

Christoph Schroeder, CEO of elea, commented that the U.S. market does not need more integration projects, but rather a unified pathology ecosystem, one where intelligence is embedded into the very fabric of the workflow.

James Thackeray, CEO of Lumea, added that by pairing elea’s intuitive interface with Lumea’s IMS Viewer+, the two companies have created what  they are calling a true Digital Diagnostic Operating System™.